Medically reviewed by Drugs.com. Last updated on May 31, 2023.
2.1 Testing Prior to the Initiation of Therapy
Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV treatment with MAVYRET [see Warnings and Precautions (5.1)].
2.2 Recommended Treatment Duration in Patients 3 Years and Older
Tables 1 and 2 provide the recommended MAVYRET treatment duration based on the patient population in HCV mono-infected and HCV/HIV-1 co-infected patients with compensated liver disease (with or without cirrhosis) and with or without renal impairment including patients receiving dialysis [see Contraindications (4) and Clinical Studies (14)]. Refer to Drug Interactions (7) for dosage recommendations for concomitant HIV-1 antiviral drugs.
|No Cirrhosis||Compensated Cirrhosis
|1, 2, 3, 4, 5, or 6||8 weeks||8 weeks|
Treated with a
|1||An NS5A inhibitor1 without prior treatment with an NS3/4A protease inhibitor (PI)||16 weeks||16 weeks|
|An NS3/4A PI2 without prior treatment with an NS5A inhibitor||12 weeks||12 weeks|
|1, 2, 4, 5, or 6||PRS3||8 weeks||12 weeks|
|3||PRS3||16 weeks||16 weeks|
2.3 Recommended Dosage in Adults
MAVYRET tablets are a fixed combination drug product containing glecaprevir 100 mg and pibrentasvir 40 mg in each tablet.
The recommended oral dosage of MAVYRET in adults is 3 tablets taken at the same time once daily with food (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg) [see Clinical Pharmacology (12.3)].
2.4 Recommended Dosage in Pediatric Patients 3 Years of Age and Older
The recommended dosage of MAVYRET in pediatric patients 3 to less than 12 years of age is based on weight. MAVYRET oral pellets are recommended for pediatric patients 3 to less than 12 years old weighing less than 45 kg. MAVYRET oral pellets in packets are a fixed combination drug product containing glecaprevir 50 mg and pibrentasvir 20 mg in each packet.
The recommended dosage of MAVYRET in pediatric patients 12 years of age and older, or in pediatric patients weighing at least 45 kg, is three tablets taken at the same time once daily with food (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).
The dosages for pediatric patients are shown in Table 3.
Table 3: Recommended Dosage in Pediatric Patients 3 Years of Age and Older
|Body Weight (kg)
or Age (yrs)
|Daily Dose of glecaprevir/pibrentasvir||Dosing of MAVYRET|
|Less than 20 kg||150 mg/60 mg per day||Three 50 mg/20 mg packets of oral pellets once daily|
|20 kg to less than 30 kg||200 mg/80 mg per day||Four 50 mg/20 mg packets of oral pellets once daily|
|30 kg to less than 45 kg||250 mg/100 mg per day||Five 50 mg/20 mg packets of oral pellets once daily|
|45 kg and greater
12 years of age and older
|300 mg/120 mg per day||Three 100 mg/40 mg tablets once daily1 (see Recommended Dosage in Adults)|
1 Pediatric patients weighing 45 kg and greater who are unable to swallow tablets may take six 50 mg/20 mg packets of oral pellets once daily. Dosing with oral pellets has not been studied for pediatric patients weighing greater than 45 kg [see Clinical Pharmacology (12.3)].
2.5 Preparation and Administration of Oral Pellets
See the MAVYRET oral pellets full Instructions for Use for details on the preparation and administration.
- The oral pellets should be taken together, with food, once daily. In addition, the oral pellets for the total daily dose should be sprinkled on a small amount of soft food with a low water content that will stick to a spoon and should be swallowed without chewing (e.g., peanut butter, chocolate hazelnut spread, cream cheese, thick jam, or Greek yogurt).
- The entire mixture of food and oral pellets should be swallowed within 15 minutes of preparation; the oral pellets should not be crushed or chewed.
- Liquids or foods that would drip or slide off the spoon are not recommended as the drug may dissolve quickly and become less effective.
2.6 Liver or Kidney Transplant Recipients
MAVYRET is recommended for 12 weeks in patients 3 years and older who are liver or kidney transplant recipients. A 16-week treatment duration is recommended in genotype 1-infected patients who are NS5A inhibitor-experienced without prior treatment with an NS3/4A protease inhibitor or in genotype 3-infected patients who are PRS treatment-experienced [see Clinical Studies (14.8)].
2.7 Hepatic Impairment
MAVYRET is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) or those with any history of prior hepatic decompensation [see Contraindications (4), Warnings and Precautions (5.2), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].
Frequently asked questions
- What is the difference between hepatitis B and C?
- How much does Mavyret cost?
- Can you drink alcohol while taking Mavyret?
- Does Mavyret make your hair fall out?
- Is Mavyret better than Harvoni?
- Can you take ibuprofen with Mavyret?
- Why take Mavyret with food?
- How long does Mavyret stay in your system?
- How long is Mavyret treatment?
More about Mavyret (glecaprevir / pibrentasvir)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (408)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: antiviral combinations
- En español
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.